PTC Therapeutics PTCT Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1?
- PTC Therapeutics (PTCT) reported business combination contingent consideration arrangements change in amount of contingent consideration asset1 of $800K in Q1 2025.
- How has PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1 changed year-over-year?
- PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1 increased by 700.0% year-over-year, from $100K to $800K.
- What is the long-term trend for PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1?
- Over 2 years (2021 to 2024), PTC Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration asset1 has grown at a 199.2% compound annual growth rate (CAGR), from $500K to $4.48M.
- What does business combination contingent consideration arrangements change in amount of contingent consideration asset1 mean?
- This represents the periodic adjustments to the fair value of earn-out obligations or contingent payments resulting from past business acquisitions. Changes in this value reflect updates to management's expectations regarding the achievement of specific clinical, regulatory, or commercial milestones. It serves as a signal of potential future cash outflows and the evolving risk profile of acquired assets.